Motor and non-motor manifestations are common and disabling features of hereditary spastic paraplegia (HSP). Botulinum toxin type A (Btx-A) is considered effective for spasticity and may improve gait in these patients. Little is known about the effects of Btx-A on non-motor symptoms in HSP patients. Objective: To assess the efficacy of Btx-A on motor and non-motor manifestations in HSP patients. Methods: Thirty-three adult patients with a clinical and molecular diagnosis of HSP were evaluated before and after Btx-A injections. Results: Mean age was 41.7 ± 13.6 years and there were 18 women. Most patients had a pure phenotype and SPG4 was the most frequent genotype. The Btx-A injections resulted in a decrease in spasticity at the adductor muscles, and no other motor measure was significantly modified. In contrast, fatigue scores were significantly reduced after Btx-A injections. Conclusion: Btx-A injections resulted in no significant functional motor improvement for HSP, but fatigue improved after treatment.
INTRODUCTION
Hereditary spastic paraplegia (HSP) comprises a heterogeneous group of neurodegenerative disorders characterized by slowly progressive spasticity and variable degrees of weakness, predominantly in the lower limbs 1, 2 . Hereditary spastic paraplegia is classified as pure or complicated, depending on the presence of additional signs or symptoms. Currently there are more than 70 different disease-loci and 50 spastic paraplegia genes (SPGs) 2, 3 . Management of spasticity in HSP using botulinum toxin injections type A (Btx-A) has been described in some studies 4, 5, 6, 7, 8 . An injection of Btx-A is considered effective and safe for the treatment of lower limb spasticity in adults 4, 6, 8, 9 ,10 and children 5 . Some studies have found that, in general, Btx-A combined with physiotherapy improves comfortable gait velocity 4, 6, 8 in HSP patients, but it is not yet known whether Btx-A improves non-motor manifestations in these patients. Non-motor manifestations are common complaints in HSP patients and, in many cases, more disabling than the motor handicap per se. They include fatigue, pain, excessive daytime sleepiness and depression. In a recent study, Servelhere et al. found that 73.3% of patients with HSP caused by SPG4 mutations had pain and 36.6% had depression 11 . Despite this significant clinical burden, much remains to be investigated on the optimal management of these manifestations.
Therefore, the aim of this study was to evaluate the efficacy of Btx-A injections, not only for motor, but also for nonmotor manifestations in HSP patients. To accomplish that, we performed a comprehensive evaluation using a panel of validated clinical scales in patients with pure and complicated forms of HSP before and after treatment.
METHODS

Patients
Thirty-three adult patients with clinical and molecular diagnoses of HSP from two Brazilian centers [Federal University of Paraná (UFPR) and University of Campinas (UNICAMP)] were evaluated before and after administration of Btx-A from February 2013 to December 2014. Patients with concomitant neurological disorders and those younger than 15 years were excluded. This research protocol was approved by each institution' s research ethics committee and a written informed consent was obtained from all patients. For each subject, we collected data on gender, age, age at onset, phenotype, genotype, inheritance pattern and interval between examinations (Table 1) .
Motor and non-motor evaluations
In order to evaluate the effects of Btx-A, we employed a comprehensive panel of instruments that assessed both motor and non-motor manifestations. All scales were validated for Brazilian Portuguese. We used three motor assessment tools for the whole sample: the Medical Research Council scale 12 to evaluate muscle strength on the ankle dorsiflexors and hip abductors; the Modified Ashworth Scale 13 to evaluate spasticity of the triceps surae and adductor muscles; and the 10-meter walk test 14 , a stop watch measure of walking speed for a standardized distance of ten meters. For those patients who scored in the range "1+" on the Ashworth scale, we considered quantification of 1.5. Gait velocity (m/s) was evaluated in a straight line, in comfortable conditions, with shoes and gait aid devices if necessary.
In addition, we were able to collect information on nonmotor symptoms for a subset of 22 patients. Five assessment tools were used for these patients: the Spastic Paraplegia Rating Scale . We also included a single item from the Spastic Paraplegia Rating Scale concerning pain. The Epworth Sleepiness Scale, Beck Depression Inventory and Modified Fatigue Impact Scale were considered abnormal if scores were higher or equal to 9, 11 and 38 respectively 16, 17, 18 .
Btx-A injections
All patients were given intramuscular injections of Btx-A (Dysport ® 500 IU) using palpatory anatomy as a means of guidance for administration. The doses and muscles to be injected were determined by the treating physicians after careful evaluation of the gait, strength and spasticity pattern of each patient. The evaluators were not aware of the injection protocol for the duration of the study. We opted to use this approach in order to simulate a realistic clinical scenario, taking into account that each individual had a specific profile of motor abnormalities (extent and severity of spasticity).
Twenty-two patients came from UNICAMP and received Btx-A injections with a mean total dosage of 1,110.0 ± 435.1 units. Of these, 19 patients received Btx-A injections in the gastrocnemius (mean dose 341.0 ± 98.9 units) and adductor muscles (mean dose 488.4 ± 165. 
Statistical analyses
Descriptive variables were expressed as mean and standard deviation. The Kolmogorov-Smirnov test was used to assess whether the data had a normal distribution. We then performed the Wilcoxon signed-rank test to compare the results of motor and non-motor scales before and after Btx-A injections. The level of significance was set at p = 0.05 for all analyses. The SPSS v 21 (IBM SPSS Statistics) was used for all statistical analyses.
RESULTS
Patients
We assessed 33 patients from UFPR (n = 11) and UNICAMP (n = 22) with a mean age of 41.7 ± 13.6 and age at onset of 22.4 ±15.8 years. There were 18 women and 15 men. Most patients had a pure phenotype (78.7%) and SPG4 was the most frequent genotype (45.4%). The mean interval between examinations was 39.7 ± 15.8 days (Table 1) .
Motor scores (n = 33)
The results of Btx-A injections on motor scores were conflicting. The main positive finding was a significant reduction of adductor spasticity (1.8 ± 1.2 x 1.4 ± 1.1, p = 0.03), shown in Figure 1 . When we compared pure and complicated HSP, no significant difference regarding motor parameters emerged.
Twenty-seven patients received Btx-A injections in hip adductor muscles. Of these, 12 patients (44.4%) had improvement: seven patients (25.9%) had a 1-point improvement; one had a 1.5-point improvement; three had a 2-point and one had a 3-point improvement. Eleven patients kept the same score and four patients had an increase of one point. After the injections, there was no significant change in terms of spasticity of the triceps surae, muscle strength of the hip abductor and ankle dorsiflexors muscles and the 10-meter walk test (Table 2) .
Non-motor scores (n = 22)
We found a significant reduction of fatigue after Btx-A injections, as shown in Figures 2 and 3 . There was an improvement, not only in the physical fatigue subset (25.4 ± 7.8 vs 19.2 ± 9.6; p = 0.011), but also of the total fatigue score (39.5 ± 14.7 vs 28.3 ±15.7; p = 0.028) (Table 3) . Interestingly, we verified that physical fatigue (on the Modified Fatigue Impact Scale physical subset) improved after Btx-A injections only in pure forms (p = 0.03) but not in complicated forms (p = 0.2).
There was no difference in the cognitive and psychosocial subsets of the Modified Fatigue Impact Scale, daytime sleepiness, depression and pain before and after Btx-A. This lack of difference was evident in the comparison between pure and complicated HSPs.
Side effects
Two patients from UNICAMP had side effects after Btx-A injections. One reported an inability to stand up and walk, slurred speech, motor slowness and handwriting incoordination 14 days after Btx-A injections. The other patient complained about excessive sleepiness, dizziness, swollen legs, and blurred vision. None of these complaints lasted longer than six months.
DISCUSSION
Botulinum toxin type A has been considered effective in treating leg spasticity muscles in different neurological disorders 20, 21 . Regarding HSPs in particular, some studies have reported variable degrees of improvement in spasticity and functional capacities, such as gait velocity 4, 5, 6, 7, 8 . In line with this, our study identified improvement in hip adductor spasticity as the main result in terms of motor manifestations. Surprisingly, there was no significant functional gain, as gait velocity remained stable between injections. This is in contrast to Rousseaux et al. 6 and Niet et al.
8
, who found positive results with Btx-A in comfortable gait velocity, but not in maximum gait speed.
Several points should be considered to clarify these differences. Firstly, different injection protocols were performed. Moreover, there was a distinct profile of the patients in each study: Rousseaux et al. and Niet et al. 8 included only patients with pure HSP and their cohorts were slightly older than ours. Other possible reasons for the negative results in the current study are the relatively low doses used and the restricted injection protocol, which included only a few muscles for each patient. Perhaps, in future studies, we could use more detailed techniques (such as gait analysis) to determine more precisely the doses and muscles to be injected in each individual. Finally, we could not ascertain whether all patients performed physical therapy on a regular basis. It is well known that the combination of Btx-A and rehabilitation significantly improves the therapeutic results. For some patients, the lack of improvement may have been due to nonadherence to the physical therapy program.
The major contribution of this study was the assessment of the effects of Btx-A on HSP-related non-motor manifestations. To the best of our knowledge, there are no studies that have looked at this specific point. We indeed found a significant improvement of fatigue after treatment, especially its physical domain. Fatigue is considered as tiredness or lack of energy 17 , and might be caused by extreme gait effort during locomotion in HSP. We hypothesize that Btx-A relieves spasticity, improves the biomechanics of gait and, therefore, improves fatigue in these subjects. When we analyzed pure and complicated forms separately, no significant differences regarding motor symptoms between groups were present. However, there was a significant difference before and after injections with respect to physical fatigue (Modified Fatigue Impact Scale physical subset) for pure forms only. A possible explanation may rely upon the fact that cognitive impairment is much more common in complicated forms of spastic paraplegia genes 22 , and this difference in fatigue may be related to a recall bias or even a distinct perception of fatigue in the cognitively-impaired subgroup of complicated HSPs.
Pain is another important and frequent non-motor feature of HSP, affecting 73.3% of patients
11
. Treatment of HSPrelated pain is an unmet medical need, and further studies on the topic are needed. The analgesic effects of Btx-A have increasingly been recognized in several chronic pain syndromes, such as migraine and other headaches 23 . In addition, a recent French, double-blind, randomized and placebocontrolled study showed the safety and efficacy of repeated administrations of Btx-A in patients with neuropathic pain 24 . Surprisingly, we were not able to demonstrate significant pain improvement after Btx-A injections. One possible explanation is that this cohort was largely pain-free (mean Brief Pain Inventory intensity score < 2), so that identification of further improvement was difficult ( floor effect). Additionally, injection protocols were different for each patient in terms of doses and injection sites. We believe that some patients may have improved, whereas others may not have. In grouping all the patients together, we may have lost statistical significance on these effects. This is perhaps the largest study to report the effects of Btx-A on HSP, but we acknowledge that it still has some important limitations. Firstly, there was no specific Btx-A injection protocol; we left the choice of doses and sites to the evaluating physicians. Although this may have introduced bias in the final analyses, we chose to perform an open uncontrolled study in order to reproduce a realistic clinical scenario, thus generating a study consistent with the daily practice of an outpatient clinic. A second limitation was the phenotypic heterogeneity of our cohort; most of the patients had pure HSP (78.7%), but some of them displayed a complicated phenotype. All those with complicated HSP had spasticity as the major complaint, but three of them also had signs of peripheral nerve damage (two of whom had SPG11 mutations), a finding that might have interfered with the efficacy and safety of Btx-A.
In conclusion, we have shown, in a mixed cohort of HSP patients, that Btx-A injections provide some benefits, not only for spasticity, but also for fatigue. These results are in line with previous reports, but the real effects of Btx-A on physical functioning and quality of life remain unclear. Available studies have conflicting results, largely due to the heterogeneity of patients, assessment tools and injection protocols. Therefore, a well-designed, placebo-controlled trial with an adequate number of patients is urgently needed to determine definitively the role of Btx-A in the management of motor and nonmotor features of patients with HSP.
